New York Times Article Spurs Xarelto Lawsuit Plaintiffs To Question FDA Approval Of Drug

March 08, 2016 – – BloodThinnerHelp.com reports on striking new revelations recently made by the New York Times concerning two major pharmaceutical companies and manufacturers of new-generation, blood-thinning drug Xarelto. The allegations, which have brought even more controversy to the topic than the mounting lawsuits discussing it, claim that Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals purposefully mislead the editors of one of the most prestigious medical journals in the world by leaving out important data concerning Xarelto.

Across the U.S., more than 3,400 Xarelto lawsuit cases have been filed, all involving plaintiffs with incredibly common complaints regarding the safety of the anticoagulant. These lawsuits are split into two main groups: 2,800 have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Eastern Louisiana, while over 600 others have been consolidated by the Court of Common Pleas to form a mass tort group in Philadelphia, Pennsylvania.

Now, however, plaintiffs are discussing more than just the products potentially dangerous and even fatal side effects. A new topic of great concern for those involved instead has become a letter which was published in The New England Journal of Medicine and authored mostly by researchers at Duke University. Plaintiffs allege that this letter intentionally left out critically important laboratory data on the drug, which may have led to its premature FDA-approval. Plaintiffs also allege that through remaining silent about this important issue, the companies intentionally misled the public. They note that after the data was published, the companies even provided the exact same data to regulators in the U.S. and in Europe.

The recent New York Times article discussing the subject insinuates that manufacturers Bayer and Johnson & Johnson, in addition to others who helped run Xarelto clinical trials at Duke University, may have lied to the editors of the New England Journal of Medicine and also pushed FDA-approval for the drug by leaving out important information for the agency to consider.

As those involved wait for more answers and as investigations into the truth continue, Attorney Joseph Osborne is working to ensure that anyone who feels they have been negatively affected by Xarelto will be provided the important opportunity to fully evaluate their legal rights in the matter. These patients may be entitled to substantial compensation. In an attempt to help those deserving pursue justice, Attorney Osborne is currently offering free legal consultations regarding Xarelto for qualifying parties.

To request additional Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008561